Login to Your Account



Clinic Roundup


Friday, July 22, 2011
Inotek Pharmaceuticals Corp., of Lexington, Mass., completed the first two of three stages of a multiple-dose Phase IIb trial of its eye drop candidate, INO-8875, in patients with glaucoma or ocular hypertension. Based on the achievement of the milestone, Inotek's investors have committed the final tranche of their previous $20 million funding round and have committed an additional $3.7 million to expand the final portion of the ongoing clinical trial by increasing the number of subjects and the duration of treatment in the final phase.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription